Nasdaq Extends Bid-Price Deadline to Feb 2027 but Flags Cy Merger as Change of Control
ENSC sits 70% above its 52-week low of $0.23 on light trading volume (0.1× avg).
Summary
Nasdaq extended Ensysce's bid-price compliance deadline to February 22, 2027, but ruled the Cy Biopharma acquisition is a Change of Control requiring initial listing approval before preferred stock conversion can proceed.
Key Events · Legal and Risk Events · ENSC
-
Bid-Price Deadline Extended to Feb 2027
Nasdaq granted an additional 180 calendar days, until February 22, 2027, to regain compliance with the $1.00 minimum bid price requirement (Rule 5550(a)(2)).
-
Cy Merger Ruled Change of Control
Nasdaq determined the Cy Biopharma transaction will result in a Change of Control under Rule 5110(a), requiring the post-transaction company to satisfy initial listing criteria and complete the initial listing process before shareholder approval of the preferred stock conversion.
-
Trading Suspension Risk
Failure to meet Nasdaq listing requirements in connection with the Cy transaction will subject the company to a suspension of trading of its securities.
-
Equity Compliance Conditioned on Next Report
Nasdaq confirmed compliance with the $2.5 million stockholders' equity requirement (Rule 5550(b)(1)) but stated the company is subject to delisting if it fails to evidence compliance in its next periodic report filed with the SEC.
Analysis · ENSC · Life Sciences
Ensysce received three Nasdaq determinations on August 25. The bid-price compliance deadline was extended 180 days to February 22, 2027, giving the company more time to lift the stock above $1.00. However, Nasdaq ruled the Cy Biopharma acquisition constitutes a Change of Control under Rule 5110(a), meaning the post-transaction company must satisfy initial listing criteria and complete the initial listing process before shareholders can approve the preferred stock conversion. Failure to meet those requirements would trigger a trading suspension. The company also must evidence stockholders' equity compliance in its next periodic report or face delisting. The Change of Control ruling adds a new regulatory hurdle to the Cy transaction that was not disclosed in the prior day's 8-K.
How filings like this one have moved
In the 30 days to Aug 25, 2026, 37.4% of the 3413 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ENSC was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8M. The 52-week trading range was $0.23 to $2.75. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.